Helen M. Thackray

Filings by Helen M. Thackray span 2 companies, the busiest being Biocryst Pharmaceuticals Inc and ImmunoGen, Inc. In total, 18 filings cover trades dated from 14 December 2021 to 31 March 2025.

On the open market, the record shows 1 purchase worth €163k and 3 sales worth €196k. Taken together, the sales exceed the purchases by €34k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 13 share grants.

The latest filing, published on 2 April 2025, reports a share grant of €52k in Biocryst Pharmaceuticals Inc. The most recent open-market purchase was published on 15 May 2024, 886 days ago. The median gap between a trade and its publication by SEC (Form 4) is 3 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.